Additionally, retrospective reviews such as the one done by Safa et al. in 2019 showed that PD‐1 monotherapy accounts for nearly 90% of ICI-related MG cases [11], whereas CTLA‐4 inhibitors alone are less often implicated. The gene discussed is PDCD1; the disease is myasthenia gravis.